Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Urine test could reduce post-op scans for kidney cancer by half

Dr Saeed Dabestani - Lund university, Lund, Sweden

Urine test could reduce post-op scans for kidney cancer by half ( Dr Saeed Dabestani - Lund university, Lund, Sweden )

Bone-protective agents given with enzalutamide with or without radium-223 show...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France

SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Assessment and management of toxic effects of cancer therapy in elderly...

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia

Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

More from ecancer